• Peer-reviewed article on Xanamem's clinical pharmacology published
• Confirms 10 mg daily dose used in current trials is appropriate
• Demonstrates value of using central pharmacodynamics to determine target dose range

Actinogen Medical has announced the publication of a peer-reviewed article in the Clinical Pharmacology in Drug Development journal, which confirms the utility of the 10 mg daily dose of Xanamem being used in the company's current clinical trials. The review demonstrates the value of using central pharmacodynamics, including positron emission tomography (PET) and computerized cognitive testing, to supplement pharmacokinetic and endocrine-based pharmacodynamics in determining the target dose range for clinical efficacy testing. Earlier pharmacokinetic modeling had suggested 20 mg daily would be optimal, but subsequent PET scanning indicated that Xanamem doses of 10 mg or even 5 mg daily may be sufficient to adequately inhibit its 11β-HSD1 enzyme target. The article also notes that with once-daily doses of 5-20 mg in cognitively normal, older volunteers, a consistent pattern of pro-cognitive benefit, without dose-response, was seen as improvement in attention and working memory but not episodic memory. Taken together, this confirms that the target dose range for Xanamem therapeutic activity is ≤ 10 mg daily and not higher.